Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–71 of 71 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Arterial Embolism and Thrombosis Clear all
Recruiting No phase listed Observational

Case-Specific Health Care Professional Clinical Survey of Liberant™ Thrombectomy System

NCT07335341
View directory record Official record
Conditions
Venous Embolism of Lower Extremities (Diagnosis), Arterial Embolism and Thrombosis, Acute DVT of Lower Extremity, Chronic DVT of Lower Extremity, DVT, Deep Vein Thrombosis Leg, Thrombus in the Peripheral Venous Vasculature, Peripheral Arterial Disease, Acute Limb Ischemia, Lower Extremity Acute Limb Ischemia, LE ALI
Interventions
Liberant Thrombectomy System
Device
Lead sponsor
Medtronic Endovascular
Industry
Eligibility
22 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Naples, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 21, 2026, 9:45 AM EDT
Completed No phase listed Observational

Patient Centered Machine Learning Model for Bleeding and Ischemic Risk

NCT06089304
View directory record Official record
Conditions
Coronary Artery Disease, Percutaneous Coronary Intervention
Interventions
Percutaneous coronary intervention
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years to 99 Years
Enrollment
19,000 participants
Timeline
2008 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Oct 21, 2026, 9:45 AM EDT
Completed Phase 3 Interventional Results available

Long Term Safety of Clopidogrel in Neonates/Infants With Systemic to Pulmonary Artery Shunt Palliation

NCT00833703
View directory record Official record
Conditions
Heart Defects, Congenital
Interventions
Clopidogrel, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Months and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 22, 2011 · Synced Oct 21, 2026, 9:45 AM EDT
Terminated Phase 4 Interventional Results available

Combined Use of BIOTRONIK Home Monitoring and Predefined Anticoagulation to Reduce Stroke Risk

NCT00559988
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter, Stroke, Embolism, Systemic Arterial, Major Bleeding
Interventions
Home Monitoring Guided OAC, Physician-Directed OAC
Drug
Lead sponsor
Biotronik, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,718 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
73
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Anaheim, California + 70 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Oct 21, 2026, 9:45 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Lower Leg Compression in Extended Video Game Play: A Pilot Study

NCT05212363
View directory record Official record
Conditions
Compression; Vein, Compression; Artery, Sedentary Behavior, DVT of Legs
Interventions
Lower extremity compression garments, Active break
Device · Behavioral
Lead sponsor
New York Institute of Technology
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Old Westbury, New York
Source: ClinicalTrials.gov public record
Updated Dec 6, 2022 · Synced Oct 21, 2026, 9:45 AM EDT
Completed No phase listed Observational

The SCRIPPS DES REAL WORLD Registry

NCT00714623
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Restenosis, Coronary Thrombosis
Interventions
Sirolimus-Eluting Bx Velocity Coronary Stent (CypherTM Sirolimus-Eluting Stent)
Device
Lead sponsor
Paul S Teirstein, MD
Other
Eligibility
18 Years and older
Enrollment
859 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Dec 24, 2012 · Synced Oct 21, 2026, 9:45 AM EDT
Completed Phase 2 Interventional

Alfimeprase for Thrombolysis in Acute Peripheral Arterial Occlusion

NCT00073554
View directory record Official record
Conditions
Arterial Occlusive Diseases, Peripheral Vascular Diseases, Thrombosis
Interventions
Alfimeprase
Drug
Lead sponsor
ARCA Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 17, 2009 · Synced Oct 21, 2026, 9:45 AM EDT
Terminated Phase 2 Interventional

Effect of ARC1779 on Cerebral Microembolism in Patients Undergoing Carotid Endarterectomy

NCT00742612
View directory record Official record
Conditions
Intracranial Embolism, Cerebral Thromboembolism, Carotid Stenosis
Interventions
ARC1779 Injection, Placebo (normal saline)
Drug
Lead sponsor
Archemix Corp.
Industry
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Hackensack, New Jersey • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2010 · Synced Oct 21, 2026, 9:45 AM EDT
Terminated No phase listed Observational

Comparison of Phase-variance Optical Coherence Tomography and Fluorescein Angiography in Retinovascular Imaging

NCT01717937
View directory record Official record
Conditions
Age-related Macular Degeneration, Diabetic Retinopathy, Hypertensive Retinopathy, Retinal Vein Occlusion, Retinal Artery Occlusion
Interventions
Phase variance optical coherence tomography (PV-OCT)
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
13 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 4, 2014 · Synced Oct 21, 2026, 9:45 AM EDT
Completed Not applicable Interventional

A Universal Electronic Health Record-based IMPROVE DD VTE Risk Assessment Model for the Prevention of Thromboembolism in Hospitalized Medically Ill Patients

NCT04768036
View directory record Official record
Conditions
Venous Thromboembolism, Arterial Thromboembolism
Interventions
IMPROVE DD VTE Tool
Other
Lead sponsor
Northwell Health
Other
Eligibility
60 Years and older
Enrollment
10,699 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Manhasset, New York • New Hyde Park, New York • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Oct 21, 2026, 9:45 AM EDT
Recruiting Phase 3 Interventional

Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease

NCT07318610
View directory record Official record
Conditions
Peripheral Artery Disease (PAD)
Interventions
REGN7508, REGN9933, Placebo, Rivaroxaban
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
7,050 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
21
States / cities
Alexander City, Alabama • Avondale, Arizona • Little Rock, Arkansas + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 21, 2026, 9:45 AM EDT
Completed Phase 4 Interventional Results available

Reversing Ticagrelor's Effects With Fresh Platelets

NCT02201394
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Ticagrelor loading dose, Aspirin loading dose, Ticagrelor maintenance dose, Aspirin maintenance dose
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Oct 21, 2026, 9:45 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Multimodal Physiologic State Intelligence Study

NCT07814118
View directory record Official record
Conditions
Heart Failure, Cardiomyopathies, Pulmonary Hypertension, Myocarditis; Acute or Subacute, Myocarditis Due to Drug, Myocarditis Viral, Pericardial Diseases, Valvular Heart Diseases, Hypertension, Sepsis, Acute Kidney Injury, Pulmonary Edema - Acute, Pulmonary Edema With Heart Failure, Pulmonary Edemas, Acute Respiratory Distress Syndrome, Pulmonary Embolism Acute, Pulmonary Embolism (Diagnosis), Pulmonary Embolism Acute Massive, Pulmonary Embolism Subacute Massive, Venous Thrombosis Pulmonary, Venous Thrombosis (Disorder), Venous Thrombosis, Deep, Peripheral Arterial Disease, Peripheral Arterial Disease (PAD), Aortic Diseases, Muskuloskeletal Diseases, Brain Aging, Brain Aneurysm, Brain Aging Related Conditions, Ultrasound, Ultrasound Exams, Ultrasound Guidance
Interventions
OMNIPHYS Multimodal Ultrasound Imaging System
Device
Lead sponsor
Truway Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2046
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 21, 2026, 9:45 AM EDT
Withdrawn No phase listed Observational

Impact of Anti-platelet Drug Exposure on Platelet mRNA Splicing in Healthy Subjects

NCT04088123
View directory record Official record
Conditions
Thrombosis; Artery
Interventions
Ticagrelor Oral Tablet [Brilinta]
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 70 Years
Timeline
2020
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 21, 2026, 9:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About How Safe BAY3018250 is and What Happens to it in Healthy Japanese Men and Adult Participants Aged 18 to 55 Years

NCT06562985
View directory record Official record
Conditions
Acute Venous and Arterial Thrombotic and Thromboembolic Events, Healthy Volunteers
Interventions
BAY3018250 Dose 1, Placebo, BAY3018250 Dose 2 infusion, BAY3018250 Dose 2 injection
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Los Alamitos, California
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Oct 21, 2026, 9:45 AM EDT
Terminated Phase 3 Interventional

Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)

NCT00557921
View directory record Official record
Conditions
Acute Coronary Syndrome, Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
Interventions
CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin, Plavix (clopidogrel 75 mg) and aspirin
Drug
Lead sponsor
Cogentus Pharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
247
States / cities
Alexander City, Alabama • Birmingham, Alabama • Geneva, Alabama + 205 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2009 · Synced Oct 21, 2026, 9:45 AM EDT
Suspended Phase 3 Interventional

Veliflapon (DG-031)to Prevent Heart Attacks or Stroke in Patients With a History of Heart Attack or Unstable Angina

NCT00353067
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
veliflapon (DG-031)
Drug
Lead sponsor
deCODE genetics
Industry
Eligibility
35 Years and older
Enrollment
3,450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
11
States / cities
Montgomery, Alabama • Jacksonville, Florida • Melrose Park, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2006 · Synced Oct 21, 2026, 9:45 AM EDT
Recruiting Phase 3 Interventional

REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis

NCT07410117
View directory record Official record
Conditions
Cancer-Associated Thrombosis (CAT)
Interventions
REGN7508, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
4
States / cities
Hialeah, Florida • North Miami Beach, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 9:45 AM EDT
Completed No phase listed Observational

Computed Tomography Dose Reduction Using Sequential or Fast Pitch Sprial Technique

NCT01272453
View directory record Official record
Conditions
Coronary Artery Disease, Aortic Aneurysm, Pulmonary Embolism
Interventions
Not listed
Lead sponsor
Gilbert L. Raff, MD
Other
Eligibility
18 Years and older
Enrollment
2,640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
8
States / cities
San Diego, California • Boston, Massachusetts • Royal Oak, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated May 30, 2014 · Synced Oct 21, 2026, 9:45 AM EDT
Completed Phase 4 Interventional

Scripps Evaluation of Antiplatelet Therapies for Intermediate Duration With the Endeavor Stent (Seaside)

NCT00963781
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Thrombosis
Interventions
Medtronic Endeavor Stent, Reduced duration (6 months) DAPT
Device · Drug
Lead sponsor
Scripps Health
Other
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2020 · Synced Oct 21, 2026, 9:45 AM EDT
Completed No phase listed Observational

Platelet Sub-study of the TWILIGHT Trial

NCT04001374
View directory record Official record
Conditions
Coronary Artery Disease, Myocardial Infarction
Interventions
Ticagrelor, ASA
Drug
Lead sponsor
Juan Badimon
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Oct 21, 2026, 9:45 AM EDT
Completed Phase 1 Interventional

MRI to Detect Embolism Following Angiography and Angioplasty-Stenting of the Renal Artery

NCT00027469
View directory record Official record
Conditions
Renal Artery Obstruction, Kidney Disease
Interventions
MRI
Procedure
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 21, 2026, 9:45 AM EDT
Recruiting Not applicable Interventional

Personalizing Thromboprophylaxis for Patients With Peripheral Artery Disease

NCT07613840
View directory record Official record
Conditions
Peripheral Arterial Disease (PAD), Amputation, Thrombosis, Thrombosis (Stent Thrombosis), Platelet Aggregation Inhibitors, Thromboelastography (TEG), PRU(Platelet Reactivity Unit)
Interventions
Aspirin, Clopidogrel, Ticagrelor, Rivaroxaban, Thromboelastography with Platelet Mapping
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • Salem, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 21, 2026, 9:45 AM EDT